US2022185778A1PendingUtilityA1
Prolyl hydroxylase inhibitors
Est. expiryNov 6, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Y02A50/30C07D 211/86A61P 7/06C07D 417/06A61K 31/501A61K 31/4427C07D 211/96A61P 29/00A61K 31/4412A61K 31/5377C07D 213/69A61P 31/10A61P 31/00A61P 31/04A61P 37/04A61K 31/497A61P 9/10A61K 31/541A61P 31/12A61K 31/55A61P 5/00A61P 35/00C07D 213/02A61P 1/00A61P 9/00C07D 491/113A61K 31/496A61K 31/444A61P 1/04A61P 17/02A61P 43/00A61K 31/44A61P 17/00A61P 33/00A61K 31/4439A61P 37/00A61P 11/00A61K 45/06C07D 401/06C07D 401/14A61K 31/4545A61P 9/12A61P 3/10C07D 401/04
80
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1α), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.
Claims
exact text as granted — not AI-modified1 - 16 . (canceled)
17 . A compound that is a pharmaceutically acceptable salt of
18 . The compound of claim 17 , wherein the compound is a pharmaceutically acceptable salt comprising an anion, wherein the anion is selected from the group consisting of chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, and citrate.
19 . The compound of claim 18 , wherein the anion is chloride.
20 . The compound of claim 18 , wherein the anion is hydrogensulfate.
21 . The compound of claim 18 , wherein the anion is p-toluenesulfonate.
22 . The compound of claim 18 , wherein the anion is methanesulfonate.
23 . A pharmaceutical composition comprising a compound that is a pharmaceutically acceptable salt of:
24 . The pharmaceutical composition of claim 23 , wherein the compound is a pharmaceutically acceptable salt comprising an anion, wherein the anion is selected from the group consisting of chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, and citrate.
25 . The pharmaceutical composition of claim 24 , wherein the anion is chloride.
26 . The pharmaceutical composition of claim 24 , wherein the anion is hydrogensulfate.
27 . The pharmaceutical composition of claim 24 , wherein the anion is p-toluenesufonate.
28 . The pharmaceutical composition of claim 24 , wherein the anion is methanesulfonate.Join the waitlist — get patent alerts
Track US2022185778A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.